Home › Breast Cancer › Indiana
Breast Cancer clinical trials in Indiana
31 studies for Breast Cancer are looking for participants at sites in Indiana.
Cities in Indiana
- Indianapolis19 studies
- Hammond9 studies
- Fort Wayne6 studies
- South Bend5 studies
- Gary4 studies
- Richmond4 studies
- Evansville3 studies
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Franciscan Health Indianapolis, Indianapolis
- Franciscan Saint Elizabeth Health - Lafayette East, Lafayette
- Franciscan Health Mooresville, Mooresville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03418961Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Research Facility, Indianapolis
RecruitingPhase 1/2
All ages · All sexes · Updated Nov 12, 2026 · NCT06590857Pilot Study of Hydroxychloroquine for the Treatment of AIMSS
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07825454A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Fort Wayne Medical Oncology and Hematology ( Site 0084), Fort Wayne
- Franciscan Health ( Site 0077), Indianapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06966700Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Community Health Network, Indianapolis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06324357Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Northwest Cancer Center, Dyer
- Indiana University, Indianapolis
Recruiting
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07214532HER2 Vaccine for Locally Advanced Breast Cancer
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06949410Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Community Health Network, Inc, Indianapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06982521A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Indiana University Health University Hospital, Indianapolis
- Hematology Oncology of Indiana, Indianapolis
- Deaconess GI Specialty Center, Newburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07174336E-Mindfulness Approaches for Living After Breast Cancer
- Goshen Center for Cancer Care, Goshen
- Baptist Health Floyd, New Albany
- Reid Health, Richmond
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Nov 4, 2026 · NCT06748222A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 4, 2026 · NCT07287098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Reid Health, Richmond
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Woodland Cancer Care Center, Michigan City
- Reid Health, Richmond
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06418204A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Indiana University (IU) School of Medicine, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07213791Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- IU Health West Hospital, Avon
- IU Health North Hospital, Carmel
- UChicago Medicine Northwest Indiana, Crown Point
- and 12 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Nov 4, 2026 · NCT05879926The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Northwest Cancer Center, Crown Point
- Northwest Cancer Center-Dyer, Dyer
- St. Mary Medical Center, Hobart
- and 2 more
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Nov 2, 2026 · NCT06377852EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Deaconess Chancellor Center for Oncology, Newburgh
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06401421A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- Research Site, Fort Wayne
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07205822Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06625775Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 45 · Women · Updated Oct 1, 2026 · NCT05557877Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Goshen Center for Cancer Care, Goshen
RecruitingObservational study
Ages 18 to 99 · All sexes · Updated Sep 3, 2026 · NCT07211178Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- IU Health Joe and Shelly Schwarz Cancer Center, Carmel
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT05846789Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Northwest Cancer Center, Dyer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06072612HER-2 B Cell Peptide Vaccine
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianpolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06414733Integrated Cancer Repository for Cancer Research
- Parkview Research Center, Fort Wayne
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Exercise in Metastatic Breast Cancer: EMBody
- Indiana University Melvin & Bren Simon Cancer Center, Indianapolis
Recruiting
Ages 18 and older · All sexes · Updated Apr 27, 2026 · NCT05468034De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Northwest Cancer Center - Main Campus, Crown Point
- UChicago Medicine Northwest Indiana, Crown Point
- Northwest Oncology LLC, Dyer
- and 9 more
RecruitingPhase 3
Ages 50 to 70 · All sexes · Updated Apr 23, 2026 · NCT04852887Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 1, 2026 · NCT05735080A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
- Research Site, Indianapolis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06956690First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Community Health Network, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2025 · NCT05216432MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- Parkview Health, Fort Wayne
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 20, 2025 · NCT03053193From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.